From Stigma to Science: The Shift in U.S. Marijuana Research

Marijuana research in the U.S. has long been hindered by regulatory challenges and scientific skepticism. Yet, recent developments suggest that the tide may be turning.

Read the full article
The Shifting Landscape of Marijuana Research in the US

About the author
Laura Kiser, Research Analyst

Transcript

Welcome to Womble Perspectives, where we explore a wide range of topics, from the latest legal updates to industry trends to the business of law. Our team of lawyers, professionals and occasional outside guests will take you through the most pressing issues facing businesses today and provide practical and actionable advice to help you navigate the ever changing legal landscape.

With a focus on innovation, collaboration and client service. We are committed to delivering exceptional value to our clients and to the communities we serve. And now our latest episode.

Marijuana research in the U.S. has long been hindered by regulatory challenges and scientific skepticism. Yet, recent developments suggest that the tide may be turning. 

The Multidisciplinary Association for Psychedelic Studies’ Phase 2 study, often referred to as MJP2, represents a critical turning point in marijuana research. After years of deliberation, the FDA approved the study to examine the safety and efficacy of inhaled high-THC cannabis for treating PTSD and physical pain. With 320 veterans participating across multiple states, and backed by a $12.9 million grant funded by Michigan’s marijuana tax revenue, the study emphasizes real-world cannabis consumption methods like smoking and vaping. 

What makes MJP2 stand out is its innovative approach to mirroring real cannabis use cases. Participants can self-titrate their THC doses, allowing them to tailor usage to individual needs while staying within a daily limit. Additionally, veterans with prior cannabis experience are included to enhance the study's relevance to clinical and non-clinical settings. 

Despite eventual approval, the study initially faced regulatory resistance. The FDA raised concerns about vaping methods and marijuana-naïve participants. Following negotiations, the Multidisciplinary Association for Psychedelic Studies’ received approval for smoking and self-titration while making updates to exclude cannabis-naïve individuals. These compromises represent a significant step forward in regulatory flexibility, setting the stage for more inclusive marijuana research.

The Schedule I classification of marijuana under the Controlled Substances Act poses an ongoing obstacle for research, equating it to substances with high abuse potential and no accepted medical use. This status complicates sourcing cannabis for scientific studies and creates a disparity between federal law and state-level legalization efforts.  

Another challenge lies in designing studies that satisfy both scientific rigor and stringent legal requirements. For instance, data on marijuana’s long-term effects on mental health conditions like PTSD remains sparse. Researchers often struggle to balance ethical, logistical, and scientific considerations when crafting research protocols.  

The FDA’s approval of the MJP2 study underscores a gradual shift in regulatory attitudes. This moment also has broader implications, signaling potential changes in the treatment of other Schedule I substances like MDMA and LSD. These milestones suggest that research into historically stigmatized substances is gaining traction among policymakers.  

The American Psychiatric Association maintains a cautious perspective on marijuana use for psychiatric conditions. Its 2019 position statements opposed cannabis as a treatment for PTSD, highlighting a lack of robust evidence. These opinions often deter clinicians from recommending marijuana despite emerging studies.  

However, there’s growing recognition within the medical community of marijuana’s potential benefits. Doctors often support its use for physical ailments like epilepsy and chronic pain but remain divided over its application for psychological disorders. Research like the MJP2 study may alleviate these concerns, gradually bridging the gap between advocates and skeptics.  

Well-designed studies like MJP2 have the potential to shape clinical guidelines and influence acceptance within the psychiatric field. By addressing evidence gaps, these studies could pave the way for marijuana to be reconsidered as a viable treatment option for PTSD and related conditions.  

Marijuana’s classification as a Schedule I drug creates significant barriers. Its status prevents widespread access for research, adds bureaucratic red tape, and perpetuates public misconceptions about its therapeutic value.  

On May 21, 2024, the DEA announced plans to reclassify marijuana from Schedule I to Schedule III under the Controlled Substances Act. This shift aligns with the Department of Health and Human Services' recommendation that marijuana has medical uses and a lower abuse potential. While the timeline remains uncertain, preliminary hearings have set the stage for meaningful change.  

Reclassifying marijuana to Schedule III could radically alter its scientific and commercial landscapes. Researchers would gain easier access, tax and banking policies could shift in favor of the cannabis industry, and the stigma surrounding marijuana use would likely diminish. It could also encourage further studies into other controlled substances, enhancing understanding and therapeutic applications.  

The expanding body of marijuana research complements increasing state-level legalization, reshaping public perceptions. Once seen primarily as a recreational drug, marijuana is steadily gaining recognition for its medical and therapeutic potential.  

Studies like MJP2 that focus on veteran populations are particularly impactful. Veterans face higher rates of conditions like PTSD and opioid addiction, making them an important demographic for assessing marijuana’s potential as an alternative treatment. Their positive experiences could bolster public and policy-level support.  

The MJP2 study and proposed reclassification of marijuana are signs of a shifting paradigm. While challenges remain, these recent advancements highlight the potential for meaningful policy changes and improved medical outcomes. 

Continued research will be critical in closing gaps in evidence, fostering innovation, and addressing skepticism within the medical community. For health professionals and policymakers alike, these developments offer new opportunities to explore marijuana’s role in medicine.  

Thank you for listening to Womble Perspectives. If you want to learn more about the topics discussed in this episode, please visit The Show Notes, where you can find links to related resources mentioned today. The Show Notes also have more information about our attorneys who provided today's insights, including ways to reach out to them.

Don't forget to subscribe via your podcast player of choice so that you never miss an episode. Thank you again for listening.